MTOR and neoplasm: However, when selecting the group of patients with pT3/pT4 tumours, those with negative expression had a median 5-year OS of 15.7 months (95% CI, 6.757–24.643), which was reduced to 3.5 months (95% CI, 1.000–8.514) if the tumours were p-mTOR positive, although the differences were not statistically significant (Fig. 2A).